

Special Issue

Advanced Research in Early Pregnancy Loss

Message from the Guest Editors

Early human pregnancy is a complex procedure involving a series of maternal endocrinological, metabolic, immunological, hematological, cellular and molecular adaptations that are critical to establish a dynamical homeostatic environment for embryo implantation, decidualization, placentation and fetal development. Accumulated evidence has shown that the disruption of this delicately modulated homeostasis will cause implantation failure, insufficient decidualization, and defective placentation. Furthermore, it can occur consecutively, i.e., recurrent implantation failure and miscarriage. Thanks to the rapid development and application of biomedicines, omics and molecular techniques, new and exciting findings have been emerging to unveil the underlying mechanism of pregnancy loss, especially in terms of maternal adaptations and maternal-fetal interactions. This Special Issue will focus on the advances and updates in the research of early pregnancy loss, including the underlying mechanisms, from signaling pathways and cellular functions, to animal studies and translational studies with potential clinical applications.

Guest Editors

Prof. Dr. Chi Chiu Wang

Department of Obstetrics & Gynaecology, The Chinese University of Hong Kong, Shatin, Hong Kong

Prof. Dr. Tao Zhang

Department of Obstetrics & Gynecology, The Chinese University of Hong Kong, Hong Kong, China

Deadline for manuscript submissions

closed (30 June 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/116829

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).